LCTX Stock Analysis: Buy, Sell, or Hold?
LCTX - Lineage Cell Therapeutics, Inc.
$1.16
-0.01 (-0.85%)
▼
5d:
-9.38%
30d:
-3.33%
90d:
-29.27%
HOLD
LOW Confidence
Analysis Updated: Jul 17, 2026 12:00 AM ET
Earnings: Aug 11, 2026
22d
Get Alerted When LCTX Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 HOLD: LCTX shows balanced signals. Fine to hold or accumulate slowly. Monitor for clearer direction.
📊 HOLD: LCTX shows balanced signals. Fine to hold or accumulate slowly. Monitor for clearer direction.
In-depth Analysis How we analyze
Valuation Analysis: LCTX is currently trading at $1.16, which is considered oversold relative to its 30-day fair value range of $1.21 to $1.31.
Technical Outlook: Technically, LCTX is in a strong downtrend. The price is currently testing key support at $1.14. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: LCTX has a weak technical setup (25/100), with bearish trendlines and momentum suggesting caution for short-term entries. Wall Street analysts see significant upside, with an average price target of $5.50 (+374.1%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Technical Outlook: Technically, LCTX is in a strong downtrend. The price is currently testing key support at $1.14. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: LCTX has a weak technical setup (25/100), with bearish trendlines and momentum suggesting caution for short-term entries. Wall Street analysts see significant upside, with an average price target of $5.50 (+374.1%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Quick Decision Summary
Current Position
OVERSOLD
Historical Trading Range
$1.21 -
$1.31
Company Quality Score
53/100
(HOLD)
Options IV Signal
39th percentile
(NORMAL)
Volume Confirmation
HIGH
Confidence Score
60.4%
All Signals
- BULLISH: Price oversold vs 30-day range
- NEUTRAL: Options fairly priced (IV 39th percentile)
- BEARISH: Weak technical setup (25/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 374.1% below Wall St target ($5.50)
- CAUTION: Recommendation downgraded due to -9.4% 5-day decline
Trading Range Analysis
30-Day Trading Range
$1.21 -
$1.31
Current vs Trading Range
OVERSOLD
Expected Move (7 Days)
±$0.29
(25.0%)
Support & Resistance Levels
Support Level
$1.14
Resistance Level
$1.38
Current Trend
Strong Downtrend
Technical data as of
Jul 17, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-12.89
Wall Street Target
$5.50
(+374.1%)
Revenue Growth (YoY)
14.8%
Share & Embed Analysis
Last updated: July 18, 2026 9:00 PM ET
Data refreshes hourly during market hours. Next update: 10:00 PM
Data refreshes hourly during market hours. Next update: 10:00 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is LCTX showing a specific setup today?
Insider Activity (6 Months)
1
Buys
0
Sells
+
Net
INSIDERS BUYING
Recent Transactions
Brian M Culley
BUY
15000 shares
2026-03-12
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
NTLA
Intellia Therapeutics Inc |
STRONG BUY
29 analysts |
$26 | 47 HOLD |
|
DNLI
Denali Therapeutics Inc |
STRONG BUY
19 analysts |
$34 | 57 HOLD |
|
NRIX
Nurix Therapeutics Inc |
STRONG BUY
18 analysts |
$32 | 63 BUY |
|
BBIO
BridgeBio Pharma Inc |
STRONG BUY
19 analysts |
$102 | 61 BUY |
|
GPCR
Structure Therapeutics I… |
STRONG BUY
14 analysts |
$105 | 51 HOLD |
